Current research and management of ovarian cancer in China

Chinese-German Journal of Clinical Oncology

Volumn 1, Issue 4, 2002, Pages 212-218

  Gu, Meijiao ^a   Shi, Wei ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Management; Ovarian cancer; Research

Indexed keywords

EID: 77956365073     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/BF02838435     Document Type: Article

References (34)

1. Shen K. The progress and challenge of chemotherapy in ovarian cancer. Chin J Clin Obstet Gynecnl, 2002, 3:3-7.
2. Shi YF, .Ye DF, Lu WG, et aL Histological classification in 10 288 cases of ovarian malignant tumors in China. Chin J Obstet Gynecol, 2002, 37:97-100
3. Lou P, Gu MJ. The epidemiology of ovarian cancer. In Gu MJ(ed). Ovarian diease. Beijing:Science, 2001. 502-508.
4. Wang Y, Wang H, Peng Z, et al. Tissue array technique for p53 expression in human ovarian neoplasms. Chin J Obstet Gynecol, 2002, 37 : 405-407.
5. Liu L, Yang K. A study on C-erbB2, nm23 mad p53 expressions in epithelial ovarian cancer and their clinical significance. Chin J Obstet Gynecol, 1999, 34:101-104.
6. Guan X, Lang J, Bian M. Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer. Chin J Obstet Gynecol, 1998, 33: 165-167.
7. Sun Y, Shen Z, Ji X. Study on the relationship between CD44v6, p53 gene mutation and ovarian carcinoma metastasis. Chin J Obstet Gynecol, 2000, 35 : 225-228.
8. Zhang GL, Xu KL. Loss of hetel, ozygosity at chromosome 3p in epithelial ovarian cancer in China. Int J Gynecol Cancer, 2002, 12: 198.
9. Zhang H, Li Z, Chen M, et al. Loss of heterccygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients. Chin J Obstet Gynecol, 2002, 37: 298-300.
10. Sham JS, Tang TC, Fang Y, et al. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet, 2002, 133:39-44.
11. Khoo US, Chan KYK, Cheung ANY, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCAI identified in the Chinese population. Hum Mutation, 2002, 486:1-7.
12. Tang NLS, Pang CP, Yeo W, et al. Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst, 1999, 91:882-885.
13. Shen K, Lang J, Huang R. Diagnosis and management strategies of hereditary ovarian cancer syndrome. Chin J Obstet Gynecol, 1996, 31 : 732-735.
14. Yang W, Zhang T, Fan J. The role of CA125 in the differential diagnosis of primary ovarian carcinoma and metastatic ovarian carcinoma originated from the gastrointestinal tract. Chin J Obstet Gynecol, 2001, 36:302-303.
15. Gu MJ. Ovarian diseases. Beijing: Science, 2001. 378-390.
16. Zang RY, Zhang ZY, Cai SM, et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res, 1999, 18:449-454.
17. Zang RY, Zhang ZY, Cai SM. Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma. Chin J Obstet Gynecol, 2002, 37:546-549.
18. Cui H. The surgical treatment of ovarian cancer. Chin J Clin Obstet Gynecol, 2001, 2 : 195-199.
19. Wang J, Zhang W. Restaging laparotomy of presumed early ovarian cancer. Chin J Obstet Gynecol, 2001, 36:672-674.
20. Shen K, Lang J, Lian L. Comprehensive staging laparotomy in stage I epithelial ovarian cancer. Chin J Obstet Gynecol, 1996, 31 : 390-394.
21. Wang CY, Gu MJ, Wang SX, et al. Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer. J Prac Obstet Gynecol, 2002, 18:228-229.
22. Huang H, Huang R, Pan L. High-dose chemotherapy with peripheralblood stem ceils transplantation in patients with advanced gynecological malignant tumors. Chin J Obstet Gynecol, 2000, 35:486-489.
23. Yang XK, Chen JH, Xing H, et al. The relationship between caspase-3 activity and chemoresistance in cisplatin-resistance human ovarian cancer cell line COC1/DDP. Frog Obstet Gynecol, 2002, 11 : 321-324.
24. Huang J, Gu M J, Chen C. Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistanee in patients with ovarian cancer. Chin J Obstet Gynecol, 1997, 32:458-461.
25. Cheng G, Zhu H, Sun L, et al. The expression of multiple drug resistanee associated genes in ovarian cancer. Chin J Obstet Gynecol, 2000, 35 : 87-90.
26. Shi W, Gu M J, Liang I.Z, et al. The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line. Clfin J Obstet G3necol, 1996, 31:79-82.
27. Gu M J, Yang ZR, Qi XM, et al. The effect of chemotherapy after eytoreductive operation on the reproduction function and the offspring of patients with ovarian cancer. Chin J Obstet Gynecol, 1993, 28 : 343-345.
28. Tong XW, Shi W, Gu MJ, et al. Animal experiment on gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction mad ganeiclovir administration in vivo. Chin J Obstet Gynecol, 1997, 32:712-714.
29. Zhang A, Lu Y, Wang S. Relationship between the expression of eonnexin 43 and bystander effect of suicide gene therapy in ovarian cancer. Chin J Obstct Gynecol, 2001, 36:542-545.
30. Yao Y, Peng Z, Wang H, et al. Anticancer effects of cytosine deaminase gene/5-fluorocytosine therapies to ovarian cancer in vivo. Chin J Obstet Gynecol, 2002, 37:195-197.
31. Li Y, Zhang Y, Li H, et at. Inhibition of recombinant rb gene adenovirus vector on the growth of ovarian cancer cell line. Chin J Obstet Gynecol, 2000, 35 : 98-100.
32. Huang X, Cai S, Fan J, et al. Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma. Chi J Obstet Gyaecol, 2002, 37:291-293.
33. Lu Y, Zhang A, Wang S, et al. Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism. Chin J Obstet Gynecol, 2002, 37 : 294-297.
34. Kong H, Jin Z, Yao M. Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaneously in nude mice. Chin J Obstet Gynecol, 2002, 37 : 556-558.